May 21, 2018

Reformulary Group Inc. Awarded the TELUS Outstanding Product Achievement Award for Mobility Health Innovation Excellence in Canada’s Health Care Sector

Reformulary Group Inc. CEO Awarded TELUS Outstanding Product Achievement Award, Mobility Health Innovation Excellence in Canada. from CATAAlliance on Vimeo.


Mike Roszak, VP, TELUS Health Solutions (lf), Helen Stevenson, Award Winner, John Reid, CATA CEO

In this five minute video, join Mike Roszak, Vice President, Health Benefits Management, TELUS Health Solutions as he presents the TELUS Outstanding Product Achievement Award for Mobility (M-Health) Innovation Excellence in Canada’s Health Care Sector to Reformulary Group Inc., Founder, President & CEO, Helen Stevenson.

In accepting the Award, Helen spoke to the importance of Canadian taking more control of their healthcare and also the company’s committment to independent researchy.

About Helen Stevenson

In 2005, Helen left her Toronto-based healthcare consulting practice to take on an entrepreneurial role in government, mandated to transform the prescription drug system in Ontario. She led the most significant prescription drug reforms in two decades saving Ontarians an unprecedented $1.5 billion over five years.

In 2007, she was appointed ADM,  Health and Executive Officer of Ontario Public Drug Programs, and oversaw Ontario’s $4 billion drug program. Helen also led many of Ontario’s drug system initiatives, including the Citizens’ Council, Drugs for Rare Diseases Framework, MedsCheck, and the Ontario Narcotics Strategy.

In 2011, having left public service, Helen founded Reformulary Group, in order to create a new subscription-based model for drug plans. The Company’s most notable innovation is its proprietary list of drugs (formulary) – the Reformulary® – which it provides on a subscription basis to Canadian employers.

The Reformulary is curated from the trusted advice of an independent panel of doctors and pharmacists that reviews massive amounts of research and evidence about each drug.

All that research and advice built into the Reformulary was put into a digital platform, called DrugFinder™ which helps plan members – and consumers – make smart drug choices and take control of their health.

Reformulary Group has an analytics business that basec on data for 11 million Canadians, comprising 1.2 billion data records. It is is a preferred venture of MaRS, the world’s largest urban innovation hub.

Helen has served as a Trustee and Governor on several Boards of Directors, including the North York General Hospital, and director of the Toronto East General Hospital Foundation. She has a BCom (McGill University), MSM (Boston University Brussels), ICD.D and has lived and worked in Belgium, Switzerland, and Canada.

About CATAAlliance
Interact with your Innovation Peer Group Now
https://www.linkedin.com/groups/37239/

The Canadian Advanced Technology Alliance (CATAAlliance) is Canada’s One Voice for Innovation Lobby Group, and is crowdsourcing ideas and guidance from thousands of opt in members in moderated social networks in Canada and key global markets. (No Tech Firm Left Behind)

Support CATA Advocacy Today through Crowdfunding

Contact: CATAAlliance CEO, John Reid at email jreid@cata.ca, tel: 613-699-8209, website: www.cata.ca, tags: Innovation, Leadership, Entrepreneurship, Advocacy